Print Page | Contact Us | Report Abuse | Sign In | Register
Graphene Updates
Blog Home All Blogs
The latest news and information on all aspects of graphene research, development, application and commercialization.

 

Search all posts for:   

 

Top tags: graphene  graphene production  Batteries  2D materials  electronics  graphene oxide  Sensors  CVD  First Graphene  University of Manchester  composites  energy storage  Carbon Nanotubes  Commercialization  Haydale  hexagonal boron nitride  Li-ion  Li-ion batteries  optoelectronics  Standards  supercapacitors  The Graphene Flagship  CealTech  CMOS  concrete  graphene platelets  ITO  masterbatches  photodetectors  photonics 

Graphene and related materials safety: human health and the environment

Posted By Graphene Council, The Graphene Council, Monday, January 28, 2019
Updated: Friday, January 25, 2019

As the drive to commercialise graphene continues, it is important that all safety aspects are thoroughly researched and understood. The Graphene Flagship project has a dedicated Work Package studying the impact of graphene and related materials on our health, as well as their environmental impact. This enables safety by design to become a core part of innovation.



Researches and companies are currently using a range of materials such as few layered graphene, graphene oxide and heterostructures. The first step to assess the toxicology is to fully characterise these materials. This work overviews the production and characterisation methods, and considers different materials, which biological effects depend on their inherent properties.

"One of the key messages is that this family of materials has varying properties, thus displaying varying biological effects. It is important to emphasize the need not only for a systematic analysis of well-characterized graphene-based materials, but also the importance of using standardised in vitro or in vivo assays for the safety assessment," says Bengt Fadeel, lead author of this paper working at Graphene Flagship partner Karolinska Institutet, Sweden.

"This review correlates the physicochemical characteristics of graphene and related materials to the biological effects. A classification based on lateral dimensions, number of layers and carbon-to-oxygen ratio allows us to describe the parameters that can alter graphene's toxicology. This can orient future development and use of these materials," explains Alberto Bianco, from Graphene Flagship partner CNRS, France and deputy leader of the Graphene Flagship Work Package on Health and Environment.

The paper gives a comprehensive overview of all aspects of graphene health and environmental impact, focussing on the potential interactions of graphene-based materials with key target organs including immune system, skin, lungs, cardiovascular system, gastrointestinal system, central nervous system, reproductive system, as well as a wide range of other organisms including bacteria, algae, plants, invertebrates, and vertebrates in various ecosystems.

"One cannot draw conclusions from previous work on other carbon-based materials such as carbon nanotubes and extrapolate to graphene. Graphene-based materials are less cytotoxic when compared to carbon nanotubes and graphene oxide is readily degradable by cells of the immune system," comments Fadeel.

Andrea C. Ferrari, Science and Technology Officer of the Graphene Flagship and Chair of its Management Panel added that "understanding any potential Health and Environmental impacts of graphene and related materials has been at the core of all Graphene Flagship activities since day one. This review provides a solid guide for the safe use of these materials, a key step towards their widespread utilization as targeted by our innovation and technology roadmap."

Tags:  Graphene  graphene oxide  Healthcare  The Graphene Flagship 

Share |
PermalinkComments (0)
 

Graphene enables a test for cancer that is faster, more accurate and less expensive!

Posted By Terrance Barkan, Monday, October 16, 2017

An international team of researchers led by Professor Steven Conlan, Swansea University Medical School and the Centre for NanoHealth has won an international award for a graphene biosensor based diagnostic test for ovarian cancer which is quicker, more accurate, less expensive and portable.

The team developed a testing device which can diagnose ovarian cancer in a few minutes using a drop of blood. This portable technology is different from the ones currently in the hospital environment and allows for greater flexibility in terms of monitoring a patient even after she has already been diagnosed with ovarian cancer.

As well as the test being simple and fast the test does not require a technically-developed laboratory or a specialized technician to operate it which reduces costs and means that there isn’t a need for a centralisation of services. The device can also be used with other biomarkers to detect other types of disease.

Ovarian cancer research award ‌Professor Conlan, together with colleagues Dr Sofia Teixeira (Swansea University College of Engineering), Drs Lewis Francis, Deya Gonzalez and Lavinia Margarit (from the Swansea University Medical School), and Dr Ines Pinto from the International Iberian Nanotechnology Laboratory, INL, Braga, Portugal have been recognised for their pioneering work with the award of the i3S Hovine Capital Health Innovation prize.
 
Professor Conlan said: “The Hovione prize will allow the team to initiate the process of moving our device from the lab to the patient. Whilst there is much work to be done, this is an important step towards the better and earlier diagnosis of patients with ovarian cancer. Cooperation between the two European centres has been key in realising this achievement.”

i3S Hovine Capital Health Innovation prize, created this year, aims at distinguishing innovative ideas in the area of health. The winners of the grand prize receive €35,000 in financing and services that include a market study, development of a business plan, technology validation by industrial experts, and support in setting up a company based on the winning technology.

The i3S-Hovione Capital Health Innovation Prize is supported internationally by the European Institute of Innovation and Technology (EIT-Health) and has partnerships with several entities, such as Bluecinical (PT), Patentree (PT), SRS Advogados (PT), Impact Science (UK), and ANI / MCTES (PT) through its Bfk Award.

Tags:  Biosensor  Cancer  Graphene  Healthcare  Medical 

Share |
PermalinkComments (0)